TargED Biopharmaceuticals clinical trials
TargED Biopharmaceuticals is the lead sponsor of 3 current clinical trials in our Spain and EU (CTIS) registers. 1 is recruiting patients now. All registered phases are Phase 1/2. The most-studied condition is Thrombotic Microangiopathies.
ClinicalTrials.gov trials by status
Trials by phase
Clinical trials sponsored by TargED Biopharmaceuticals
1 on ClinicalTrials.gov| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
TGD001 Treatment in Thrombotic Microangiopathies
NCT07459114 · ClinicalTrials.gov ↗ · Thrombotic Microangiopathies, ITP Immune-Mediated Thrombocytopenia
|
Phase 1/2 | Recruiting | 2026-10 | Spain |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
TargED Biopharmaceuticals in the EU trials register (CTIS)
2 trialsAuthorised or ongoing trials in the EU Clinical Trials Information System with TargED Biopharmaceuticals as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Countries |
|---|---|---|---|
|
An Adaptive Dose Escalation and Expansion Basket Trial to Explore the Safety, Pharmacology, and Clinical Activity of TGD001 in Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP) and Other Thrombotic Microangiopathies
2025-523802-34-00 · CTIS ↗ · Hemic and Lymphatic Diseases
|
Phase 1 | Ongoing | Germany, France, Italy + 1 more |
|
A Phase 1b/2a Open-Label Dose-Finding Followed by Randomized, Double-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of TGD001 in Patients with Acute Ischemic Stroke
2025-522455-26-00 · CTIS ↗ · Nervous System Diseases
|
Phase 1 | Ongoing | Poland, Germany, Spain |
Conditions in TargED Biopharmaceuticals trials
2 conditionsBy trial register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Spain | 1 | 1 |
| EU register (CTIS) | 2 | — |
A trial with sites in more than one country appears in each of those registers.
Questions about TargED Biopharmaceuticals trials
How many clinical trials does TargED Biopharmaceuticals sponsor?
TargED Biopharmaceuticals is the lead sponsor of 1 current trial on ClinicalTrials.gov in our Spain register, and 2 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 14 November 2026. Completed and withdrawn studies are not counted.
Are TargED Biopharmaceuticals trials recruiting?
Yes. 1 of its 1 ClinicalTrials.gov trial is recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Where does this information come from?
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
How this page is built
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
- EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 14 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.